Shandong Boan Biotechnology Wins China Approval for Boyoujing Aflibercept Injection
Shandong Boan Biotechnology Co. Ltd. has received marketing approval from China's National Medical Products Administration for its aflibercept injection, Boyoujing®, a biosimilar to EYLEA®, for treating nAMD and DME. The company will partner with Ocumension Therapeutics to commercialize the product in Mainland China, marking a significant milestone in expanding ophthalmic treatment access.
Shandong Boan Biotechnology Co. Ltd. has announced that China’s National Medical Products Administration has granted marketing approval for its aflibercept intravitreous injection, Boyoujing®. The product, a biosimilar to EYLEA®, is indicated for the treatment of neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME) in adults. Shandong Boan will collaborate with Ocumension Therapeutics to commercialize Boyoujing® in the Chinese Mainland. The approval marks a significant milestone for the company as it seeks to expand access to ophthalmic treatments in China. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shandong Boan Biotechnology Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251126-11929021), on November 26, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
